8V8 Stock Overview
A science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Genetic Analysis AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.20 |
| 52 Week High | NOK 0.20 |
| 52 Week Low | NOK 0.017 |
| Beta | 1.9 |
| 1 Month Change | 362.79% |
| 3 Month Change | 659.54% |
| 1 Year Change | 429.26% |
| 3 Year Change | -34.21% |
| 5 Year Change | n/a |
| Change since IPO | -80.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8V8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 132.7% | 1.2% | 2.5% |
| 1Y | 429.3% | -14.9% | 14.4% |
Return vs Industry: 8V8 exceeded the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: 8V8 exceeded the German Market which returned 14.4% over the past year.
Price Volatility
| 8V8 volatility | |
|---|---|
| 8V8 Average Weekly Movement | 58.3% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 8V8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8V8's weekly volatility has increased from 45% to 58% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 21 | Ronny Hermansen | www.genetic-analysis.com |
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Collection Kit used for collection, transport, and storage of fecal specimens for nucleic acid analyses; and GA-map Covid-19 Fecal Test, a non-invasive test with an easy-to-use home sampling procedure.
Genetic Analysis AS Fundamentals Summary
| 8V8 fundamental statistics | |
|---|---|
| Market cap | €8.90m |
| Earnings (TTM) | -€1.26m |
| Revenue (TTM) | €1.76m |
5.1x
P/S Ratio-7.1x
P/E RatioIs 8V8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8V8 income statement (TTM) | |
|---|---|
| Revenue | NOK 20.68m |
| Cost of Revenue | NOK 3.11m |
| Gross Profit | NOK 17.57m |
| Other Expenses | NOK 32.34m |
| Earnings | -NOK 14.77m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 27, 2025
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 84.95% |
| Net Profit Margin | -71.40% |
| Debt/Equity Ratio | 20.9% |
How did 8V8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 08:43 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genetic Analysis AS is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gediminas Ruginis | Norne Securities AS |